PTC Therapeutics Inc (PTCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Dec-2017

No. of Pages : 78

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PTC Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
PTC Therapeutics Acquires US Rights to Emflaza from Marathon Pharma 12
Venture Financing 14
PTC Therapeutics Raises US$60 Million In Venture Financing 14
PTC Therapeutics Raises US$2 Million In Venture Financing 16
Ptc Therapeutics Raises US$30 Million In Venture Financing 17
Partnerships 18
PTC Therapeutics Enters into Agreement with University of Pennsylvania 18
Pint Pharma Enter into Co-operation Agreement with PTC Therapeutics 19
Dualsystems Biotech Enters Into Agreement With PTC Therapeutics For Drug Profiling 20
PTC Therapeutics Expands Its Collaboration With Parent Project Muscular Dystrophy 21
Licensing Agreements 22
Roche Enters Into Licensing Agreement With PTC Therapeutics And SMA Foundation 22
PTC Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 23
AstraZeneca Enters Into Collaboration And Licensing Agreement With PTC Therapeutics 24
Equity Offering 25
PTC Therapeutics Raises USD125 Million in Public Offering of Shares 25
PTC Therapeutics Completes Public Offering Of Shares For US$126.5 Million 27
PTC Therapeutics Completes IPO For US$144.4 Million 29
Debt Offering 31
PTC Therapeutics Raises USD150 Million in Private Placement of 3% Notes Due 2022 31
Acquisition 33
Sanofi May Acquire PTC Therapeutics 33
PTC Therapeutics Inc - Key Competitors 34
PTC Therapeutics Inc - Key Employees 35
PTC Therapeutics Inc - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 38
Financial Announcements 38
Nov 02, 2017: PTC Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 38
Aug 08, 2017: PTC Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 40
May 08, 2017: PTC Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 42
Mar 16, 2017: PTC Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 43
Jan 09, 2017: PTC Therapeutics Provides Corporate Update and Outlines 2017 Strategic Priorities to Maximize the Global Value of Translarna and Advance its Innovative Pipeline 45
Nov 02, 2016: PTC Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update 46
Aug 04, 2016: PTC Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update 48
May 05, 2016: PTC Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update 50
Feb 29, 2016: PTC Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update 52
Corporate Communications 54
Jul 24, 2017: PTC Therapeutics Announces Promotion of Dr. Joseph McIntosh to Senior Vice President and Head of Clinical Development 54
Jun 05, 2017: PTC Therapeutics Announces Executive Promotions 55
Apr 10, 2017: PTC Therapeutics Announces Departure of Chief Financial Officer, Shane Kovacs 56
Jun 13, 2016: PTC Therapeutics Appoints Dawn Svoronos to Board of Directors 57
Apr 26, 2016: PTC Therapeutics Appoints Dr. Tuyen Ong as Chief Medical Officer 58
Government and Public Interest 59
Feb 08, 2017: PTC Therapeutics Announces Third Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy 59
Feb 12, 2016: PTC Therapeutics Announces Second Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy 60
Product News 61
04/15/2016: NICE recommends ataluren for treating Duchenne muscular dystrophy caused by a nonsense mutation 61
03/23/2016: PTC Therapeutics Announces Workforce Reduction as Part of Operating Expense Management Plan 63
03/09/2016: Marathon Pharmaceuticals Announces Nationwide Expanded Access Program for Patients with Duchenne Muscular Dystrophy 64
02/26/2016: PTC Therapeutics Provides Update on German pricing and Reimbursement Process for Translarna (ataluren) 65
Product Approvals 66
Feb 09, 2017: FDA Approves EMFLAZA (deflazacort) Tablets and Oral Suspension for the Treatment of Duchenne Muscular Dystrophy in Patients 5 Years and Older 66
Aug 10, 2016: FDA Accepts Marathon Pharmaceuticals New Drug Applications for Deflazacort for the Treatment of Duchenne Muscular Dystrophy and Grants Priority Review 67
Jun 14, 2016: Marathon Pharmaceuticals Announces Submission of Deflazacort New Drug Application to the FDA 68
Mar 14, 2016: PTC Therapeutics Provides Update on Health Canada Review of Translarna (ataluren) for the Treatment of Duchenne Muscular Dystrophy 69
Feb 23, 2016: PTC Receives Refuse to File Letter from FDA for Translarna (ataluren) 70
Jan 11, 2016: PTC Therapeutics Outlines Business Priorities for the Development and Commercialization of Translarna and Progress of the Company Pipeline 71
Jan 08, 2016: PTC Completes Rolling NDA Submission to FDA and Submits Phase 3 ACT DMD Clinical Trial Results to EMA for Translarna (ataluren) for Treatment of Nonsense Mutation Duchenne Muscular Dystrophy 72
Clinical Trials 73
Sep 08, 2016: Study Could Herald New Treatment for Muscular Dystrophy 73
Aug 30, 2016: Marathon Pharmaceuticals Announces Neurology Publication of Pivotal Phase 3 Data for Deflazacort for Duchenne Muscular Dystrophy 74
Apr 19, 2016: Marathon Pharmaceuticals Presents Analyses at AAN of a Phase III Clinical Study of Deflazacort in Patients with Duchenne Muscular Dystrophy (DMD) 75
Mar 14, 2016: PTC Therapeutics Announces Presentation of Results from Phase 3 ACT DMD Clinical Trial of Translarna (ataluren) in Patients with Duchenne Muscular Dystrophy at 5th International Congress of Myology 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78

List of Tables
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PTC Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PTC Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
PTC Therapeutics Acquires US Rights to Emflaza from Marathon Pharma 12
PTC Therapeutics Raises US$60 Million In Venture Financing 14
PTC Therapeutics Raises US$2 Million In Venture Financing 16
Ptc Therapeutics Raises US$30 Million In Venture Financing 17
PTC Therapeutics Enters into Agreement with University of Pennsylvania 18
Pint Pharma Enter into Co-operation Agreement with PTC Therapeutics 19
Dualsystems Biotech Enters Into Agreement With PTC Therapeutics For Drug Profiling 20
PTC Therapeutics Expands Its Collaboration With Parent Project Muscular Dystrophy 21
Roche Enters Into Licensing Agreement With PTC Therapeutics And SMA Foundation 22
PTC Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 23
AstraZeneca Enters Into Collaboration And Licensing Agreement With PTC Therapeutics 24
PTC Therapeutics Raises USD125 Million in Public Offering of Shares 25
PTC Therapeutics Completes Public Offering Of Shares For US$126.5 Million 27
PTC Therapeutics Completes IPO For US$144.4 Million 29
PTC Therapeutics Raises USD150 Million in Private Placement of 3% Notes Due 2022 31
Sanofi May Acquire PTC Therapeutics 33
PTC Therapeutics Inc, Key Competitors 34
PTC Therapeutics Inc, Key Employees 35
PTC Therapeutics Inc, Other Locations 36
PTC Therapeutics Inc, Subsidiaries 36

List of Figures
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

PTC Therapeutics Inc (PTCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027